miR-93-5p Suppresses Ovarian Cancer Malignancy and Negatively Regulate CCND2 By Binding To Its 3’UTR Region

Ovarian cancer is the most lethal gynecological cancer worldwide, but the underlying mechanism of ovarian cancer malignancy acquirement is largely unknown. miRNA is ubiquitously implicated in disease especially in cancer initiation and progression. In current study, we firstly detected the expression level of miR-93-5p in ovarian cancer patient samples and conducted a survival analysis. Our data revealed miR-93-5p is a favorable prognostic factor but is downregulated in ovarian cancer patients. Secondly, CCK8 assay wound healing assay and flow cytometry-based cell cycle analysis and apoptotic cell analysis were performed respectively to study the function of miR-93-5p. Functional analysis show miR-93-5p promotes ovarian cancer malignancy in term of cell proliferation, migration but reduce cell death. Bioinformatic analysis showed Cyclin-D2(CCND2) is a candidate gene of miR-93-5p with the binding site in its 3’UTR region. Furthermore, quantitive-PCR and western blot were utilized to measure miR-93-5p, CCND2 levels in tissues samples and cell lines. Our data suggested miR-93-5p is negatively correlated to the level of CCND2 mRNA and protein. Finally, Luciferase report assay was conducted, and we demonstrated miR-93-5p reduces CCND2 expression by binding to the 3’UTR region. Our study revealed the function of miR-93-5p in ovarian cancer malignancy and declaimed CCND2 as a target of miR-93-5p.

A Case of Stevens–Johnson Syndrome in Recurrent Late-Stage Ovarian Cancer Patient after Management of Chronic Pain with Elastomeric Pump

(1) Background. Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe mucocutaneous reactions, characterized by extensive necrosis and detachment of the epidermis. (2) Case presentation. We present a case of a 46-year-old patient with late-stage high-grade serous ovarian cancer who was primarily treated with neoadjuvant chemotherapy and interval debulking, which was followed by adjuvant chemotherapy. At first recurrence, she was again treated with chemotherapy, and due to severe abdominal pain, an elastomeric pump containing analgesics, anti-inflammatories, and ondansetron was administered. In the same month, she was admitted to the hospital due to severe dysphagia, and in the following days she developed haemorrhagic vesiculobullous lesions on the facial skin and trunk. Stevens–Johnson syndrome was confirmed and ondansetron as a plausible leading cause was discontinued. Despite multimodal treatment, her condition deteriorated, and she died. (3) Discussion and conclusion. Although gynaecologists rarely encounter Stevens–Johnson syndrome, high mortality of the disease should ensure a low threshold for diagnosing and treating this disease.

Patent foramen ovale presenting with platypnoea-orthodeoxia syndrome and stroke after multi-organ resection

Platypnoea-orthodeoxia syndrome (POS) is defined by oxygen desaturation and dyspnoea in upright position that improves by lying down. It results from a right to left shunt at the intracardiac or intrapulmonary level. A 53-year-old ovarian cancer patient presented with POS that was refractory to oxygen therapy. The symptoms began after an extensive abdominal and pelvic surgery as treatment of her cancer with a complex hospital course. A patent foramen ovale was found with the use of transoesophageal echocardiography. A percutaneous closure was done with positive outcome and dyspnoea disappearance. In this case with its challenging clinical setting, we present a unique clinical scenario of an immediate postoperative POS syndrome. We address the different therapeutic modalities and the need for a multidisciplinary medical approach.